This list is an analysis based on recent market events. It's not an investment recommendation.
About
Health Technology
Pharmaceuticals: Other
Manufacturing
Pharmaceutical Preparation Manufacturing
PLx Pharma Inc. operates as a commercial-stage drug delivery platform technology company in the United States. The company's lead product candidates are Vazalore 325 mg for the patients with vascular events, such as heart attacks and clot-related strokes, as well as for use in conditions associated with pain and inflammation, including other aspirin and non-steroidal anti-inflammatory drug products; and Vazalore 81 mg liquid-filled aspirin capsules. Its product pipeline also includes PL1200 Ibuprofen 200 mg; and PL1100 Ibuprofen 400 mg, which are in Phase I clinical stage for pain, inflammation, and fever. The company sells its products through drugstores, mass merchandisers, grocery stores, and e-commerce channels. PLx Pharma Inc. was incorporated in 2002 and is headquartered in Sparta, New Jersey.
Show more...
CEO
Employees
16
Country
US
ISIN
US72942A1079
WKN
000A2DMUN
Listings
0 Comments
Share your thoughts
FAQ
What is PLx Pharma stock price today?▼
The current price of PLXP is $0.04 USD — it has decreased by -52.76% in the past 24 hours. Watch PLx Pharma stock price performance more closely on the chart.
What is PLx Pharma stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange PLx Pharma stocks are traded under the ticker PLXP.
What is PLx Pharma market cap?▼
Today PLx Pharma has the market capitalization of 1.2M
What is PLx Pharma revenue for the last year?▼
PLx Pharma revenue for the last year amounts to 8.21M USD.
What is PLx Pharma net income for the last year?▼
PLXP net income for the last year is -46.13M USD.
How many employees does PLx Pharma have?▼
As of April 01, 2026, the company has 16 employees.
In which sector is PLx Pharma located?▼
PLx Pharma operates in the Manufacturing sector.
When did PLx Pharma complete a stock split?▼
The last stock split for PLx Pharma was on April 20, 2017 with a ratio of 1:8.